Alpaslan Dedeoglu, MD, PhD

Associate Professor, Neurology

Alpaslan Dedeoglu
150 S Huntington Avenue


Dr. Alpaslan Dedeoglu received his MD from the Istanbul University School of Medicine and completed a pharmacology program at the Marmara University in 1992. During and after his pharmacology program he worked at the University of Arizona, Ohio State University, and Massachusetts General Hospital; he then joined Boston University in 2000. Dr. Dedeoglu’s major research interests are neuroanatomy, neuropathology, and the neurochemistry of animal models of neurodegenerative disorders. His labs are located at the Boston VA Medical Center. Dr. Dedeoglu is the PI of several ongoing projects that are funded by the NIH, VA, and private foundations. He also works with therapeutic trials in rodent models of neurodegenerative disorders.

Other Positions

  • VA Boston Healthcare System
  • Graduate Faculty (Primary Mentor of Grad Students), Boston University Chobanian & Avedisian School of Medicine, Graduate Medical Sciences


  • Istanbul University, MD
  • Marmara University, PhD


  • Published on 3/26/2024

    Ay B, Cyr SM, Klovdahl K, Zhou W, Tognoni CM, Iwasaki Y, Rhee EP, Dedeoglu A, Simic P, Bastepe M. Ga11 deficiency increases fibroblast growth factor 23 levels in a mouse model of familial hypocalciuric hypercalcemia. JCI Insight. 2024 Mar 26; 9(9). PMID: 38530370.

    Read at: PubMed
  • Published on 6/14/2023

    Almarhoumi R, Alvarez C, Harris T, Tognoni CM, Paster BJ, Carreras I, Dedeoglu A, Kantarci A. Microglial cell response to experimental periodontal disease. J Neuroinflammation. 2023 Jun 14; 20(1):142. PMID: 37316834.

    Read at: PubMed
  • Published on 5/7/2023

    Carreras I, Jung Y, Lopez-Benitez J, Tognoni CM, Dedeoglu A. Fingolimod mitigates memory loss in a mouse model of Gulf War Illness amid decreasing the activation of microglia, protein kinase R, and NF?B. Neurotoxicology. 2023 May; 96:197-206. PMID: 37160207.

    Read at: PubMed
  • Published on 11/18/2022

    Jung Y, Lopez-Benitez J, Tognoni CM, Carreras I, Dedeoglu A. Dysregulation of sphingosine-1-phosphate (S1P) and S1P receptor 1 signaling in the 5xFAD mouse model of Alzheimer's disease. Brain Res. 2023 Jan 15; 1799:148171. PMID: 36410428.

    Read at: PubMed
  • Published on 6/23/2022

    Wu H, Qiu W, Zhu X, Li X, Xie Z, Carreras I, Dedeoglu A, Van Dyke T, Han YW, Karimbux N, Tu Q, Cheng L, Chen J. The Periodontal Pathogen Fusobacterium nucleatum Exacerbates Alzheimer's Pathogenesis via Specific Pathways. Front Aging Neurosci. 2022; 14:912709. PMID: 35813949.

    Read at: PubMed
  • Published on 10/13/2021

    Ma KS, Hasturk H, Carreras I, Dedeoglu A, Veeravalli JJ, Huang JY, Kantarci A, Wei JC. Dementia and the Risk of Periodontitis: A Population-Based Cohort Study. J Dent Res. 2022 03; 101(3):270-277. PMID: 34643147.

    Read at: PubMed
  • Published on 10/29/2020

    Kantarci A, Tognoni CM, Yaghmoor W, Marghalani A, Stephens D, Ahn JY, Carreras I, Dedeoglu A. Microglial response to experimental periodontitis in a murine model of Alzheimer's disease. Sci Rep. 2020 10 29; 10(1):18561. PMID: 33122702.

    Read at: PubMed
  • Published on 3/6/2020

    Pilozzi A, Yu Z, Carreras I, Cormier K, Hartley D, Rogers J, Dedeoglu A, Huang X. A Preliminary Study of Cu Exposure Effects upon Alzheimer's Amyloid Pathology. Biomolecules. 2020 03 06; 10(3). PMID: 32155778.

    Read at: PubMed
  • Published on 7/29/2019

    Carreras I, Aytan N, Choi JK, Tognoni CM, Kowall NW, Jenkins BG, Dedeoglu A. Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease. Sci Rep. 2019 07 29; 9(1):10972. PMID: 31358793.

    Read at: PubMed
  • Published on 11/29/2018

    Korkmaz OT, Ay H, Aytan N, Carreras I, Kowall NW, Dedeoglu A, Tuncel N. Vasoactive Intestinal Peptide Decreases ß-Amyloid Accumulation and Prevents Brain Atrophy in the 5xFAD Mouse Model of Alzheimer's Disease. J Mol Neurosci. 2019 Jul; 68(3):389-396. PMID: 30498985.

    Read at: PubMed

View 47 more publications: View full profile at BUMC

View all profiles